Related Experiment Video
Updated: Jun 6, 2025
06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
526
Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update
Nicia I Profili1, Roberto Castelli1, Antonio Gidaro2
1Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.
Pharmaceuticals (Basel, Switzerland)
|November 27, 2024
Summary
Sodium-glucose cotransporter-2 inhibitors, initially for type 2 diabetes, show significant benefits for heart failure patients. These drugs improve cardiovascular health and manage heart failure, regardless of diabetes status.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Diabetes mellitus and heart failure frequently coexist, particularly in elderly patients.
- Elevated blood glucose levels adversely affect the cardiovascular system, worsening glycemic control.
- Poor glycemic control exacerbates the onset and recurrence of heart failure.
Purpose of the Study:
- To review the efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) in managing heart failure.
- To explore the cardiovascular benefits of SGLT2 inhibitors beyond glycemic control.
Main Methods:
- Analysis of clinical trials and studies on SGLT2 inhibitors.
- Examination of the mechanisms underlying SGLT2 inhibitor action in heart failure.
Main Results:
- SGLT2 inhibitors reduce blood glucose via glycosuria, lowering cardiovascular risk.
- These inhibitors possess a diuretic effect beneficial for heart failure management.
- Evidence suggests SGLT2 inhibitors improve heart failure treatment irrespective of glycemic control.
Conclusions:
- SGLT2 inhibitors demonstrate efficacy in treating both chronic and acute heart failure.
- The cardiovascular benefits of SGLT2 inhibitors extend to patients without diabetes mellitus.
- SGLT2 inhibitors represent a significant therapeutic advancement for heart failure management.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
174
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174
01:26Heart Failure Drugs: Inotropic Agents
521
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
521
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
159
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
159
01:23Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171
01:22Heart Failure Drugs: Diuretics
343
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
343